[go: up one dir, main page]

HK1210011A1 - N-{[(7s)-3,4-二甲氧二环[4.2.0]辛-1,3,5-三烯-7-基]甲基}-3-(7,8-二甲氧基-1,2,4,5-四氢-3h-3-苯并氮杂䓬-3-基)-n-甲基-3-氧代-1-丙胺和培哚普利的组合 - Google Patents

N-{[(7s)-3,4-二甲氧二环[4.2.0]辛-1,3,5-三烯-7-基]甲基}-3-(7,8-二甲氧基-1,2,4,5-四氢-3h-3-苯并氮杂䓬-3-基)-n-甲基-3-氧代-1-丙胺和培哚普利的组合 Download PDF

Info

Publication number
HK1210011A1
HK1210011A1 HK15110660.1A HK15110660A HK1210011A1 HK 1210011 A1 HK1210011 A1 HK 1210011A1 HK 15110660 A HK15110660 A HK 15110660A HK 1210011 A1 HK1210011 A1 HK 1210011A1
Authority
HK
Hong Kong
Prior art keywords
methyl
perindopril
dimethoxybicyclo
octa
dimethoxy
Prior art date
Application number
HK15110660.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1210011B (zh
Inventor
Christian Thuillez
Paulus Mulder
Jean-Paul Vilaine
Marie-Dominique Fratacci
Guy Lerebours-Pigeonniere
Luc Feldmann
Jérôme Roussel
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1210011(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HK1210011A1 publication Critical patent/HK1210011A1/zh
Publication of HK1210011B publication Critical patent/HK1210011B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15110660.1A 2010-06-15 2015-10-28 N-{[(7s)-3,4-二甲氧二环[4.2.0]辛-1,3,5-三烯-7-基]甲基}-3-(7,8-二甲氧基-1,2,4,5-四氢-3h-3-苯并氮杂䓬-3-基)-n-甲基-3-氧代-1-丙胺和培哚普利的组合 HK1210011B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1002525A FR2961105B1 (fr) 2010-06-15 2010-06-15 Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
FR1002525 2010-06-15

Publications (2)

Publication Number Publication Date
HK1210011A1 true HK1210011A1 (zh) 2016-04-15
HK1210011B HK1210011B (zh) 2017-02-17

Family

ID=

Also Published As

Publication number Publication date
ZA201104222B (en) 2012-02-29
AU2011202607B2 (en) 2015-02-12
ME02163B (me) 2015-10-20
HUE027088T2 (en) 2016-08-29
NZ600931A (en) 2013-04-26
TWI468164B (zh) 2015-01-11
WO2011157908A8 (fr) 2013-01-17
SG10201500502WA (en) 2015-03-30
TN2012000551A1 (fr) 2014-04-01
AP3691A (en) 2016-04-30
BRPI1102830B1 (pt) 2019-10-08
IL223293A0 (en) 2013-02-03
SG177069A1 (en) 2012-01-30
PT2404600E (pt) 2015-07-13
DK2404600T3 (en) 2015-08-31
SA111320527B1 (ar) 2015-03-19
US20110306598A1 (en) 2011-12-15
SA114360089B1 (ar) 2016-02-03
JO3309B1 (ar) 2018-09-16
AP2016009002A0 (en) 2016-01-31
PL2404600T3 (pl) 2015-10-30
NZ593437A (en) 2012-08-31
KR20110136752A (ko) 2011-12-21
TW201206445A (en) 2012-02-16
PH12012502315A1 (en) 2013-02-04
BRPI1102830A2 (pt) 2013-12-24
CN102284060A (zh) 2011-12-21
NI201200182A (es) 2013-05-13
ME02476B (me) 2017-02-20
FR2961105B1 (fr) 2013-02-08
EA201100773A1 (ru) 2011-12-30
PL2921168T3 (pl) 2016-10-31
FR2961105A1 (fr) 2011-12-16
EP2921168A1 (fr) 2015-09-23
MA33235B1 (fr) 2012-05-02
PH12012502315B1 (en) 2020-09-18
SI2404600T1 (sl) 2015-10-30
CA2743527A1 (fr) 2011-12-15
CL2011001420A1 (es) 2012-07-06
MY179034A (en) 2020-10-26
ECSP12012337A (es) 2012-12-28
HK1210012A1 (zh) 2016-04-15
BRPI1102830B8 (pt) 2020-01-07
HUE027788T2 (en) 2016-10-28
CU24161B1 (es) 2016-03-31
AU2011202607A1 (en) 2012-01-12
GT201200341A (es) 2014-03-14
IL223293A (en) 2017-04-30
JP5480202B2 (ja) 2014-04-23
JP2012001545A (ja) 2012-01-05
CR20120609U (es) 2013-02-05
CU20120166A7 (es) 2013-04-19
UY33423A (es) 2011-12-30
EP2404600A1 (fr) 2012-01-11
CY1116438T1 (el) 2017-02-08
UA108983C2 (en) 2015-07-10
ES2582157T3 (es) 2016-09-09
WO2011157908A1 (fr) 2011-12-22
CO6640265A2 (es) 2013-03-22
CY1117724T1 (el) 2017-05-17
CN104906579A (zh) 2015-09-16
MX2011006001A (es) 2011-12-14
SI2921168T1 (sl) 2016-08-31
AR081875A1 (es) 2012-10-24
RS54077B1 (sr) 2015-10-30
AP2013006661A0 (en) 2013-01-31
EP2404600B1 (fr) 2015-05-27
CA2743527C (fr) 2016-08-02
EP2921168B1 (fr) 2016-04-13
KR101389879B1 (ko) 2014-04-29
GEP20146132B (en) 2014-08-11
EA022612B1 (ru) 2016-02-29
HRP20160643T1 (hr) 2016-07-01
PE20120019A1 (es) 2012-02-11
RS54838B1 (sr) 2016-10-31
DK2921168T3 (en) 2016-08-01
BRPI1102830F1 (pt) 2022-03-29
ES2545343T3 (es) 2015-09-10
HRP20150745T1 (hr) 2015-08-14

Similar Documents

Publication Publication Date Title
MXPA06012116A (es) Uso de flibanserina en el tratamiento del trastornos premestruales y otros trastornos sexuales femeninos.
DK2921168T3 (en) Combination of N - {[(7S) -3,4-dimethoxybicyclo [4.2.0] octa-1,3,5-trien-7-yl] methyl} -3- (7,8-dimethoxy-1,2, 4,5-Tetrahydro-3H-3-benzazepin-3-yl) -n-methyl-3-oxo-1-propanamine and perindopril
US20120196850A1 (en) ASSOCIATION OF A SINUS NODE If CURRENT INHIBITOR AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
US11931341B2 (en) Compositions and methods for the treatment and prevention of muscular dystrophy
HK1210011B (zh) N-{[(7s)-3,4-二甲氧二环[4.2.0]辛-1,3,5-三烯-7-基]甲基}-3-(7,8-二甲氧基-1,2,4,5-四氢-3h-3-苯并氮杂䓬-3-基)-n-甲基-3-氧代-1-丙胺和培哚普利的组合
KR101078133B1 (ko) 동방 결절 if 흐름 억제제와 베타 차단제의 회합체
CN101015556B (zh) 窦房结If电流抑制剂与钙抑制剂的组合以及含有它的药物组合物
EP4424309A1 (en) Composite composition containing angiotensin receptor blocker and sglt2 inhibitor
HU201244B (en) Process for production of medical compositions containing as active substance derivatives of quinoline applicable for treatment of heart-arithmia
HK1165283A (zh) 窦房结if当前抑制剂和血管紧张素转化酶抑制剂的组合在治疗心力衰竭中的用途
OA16276A (fr) Utilisation de l'association d'un inhibiteur du courant IF sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220609